

Suppl. Table 1. Sensitivity of RITA-adapted UKF-NB-3 sub-lines to RITA and nutlin-3-adapted sub-lines to nutlin-3 before and after cultivation for 10 passages in the absence of the corresponding drugs as indicated by the concentration that inhibits cell viability by 50% (IC₅₀) after five days of incubation.

Cell line	p53 status	IC ₅₀	IC ₅₀ after 10 passages in the absence of drug
		RITA (μM)	RITA (μM)
UKF-NB-3 ^r RITA ^{10μM}	wt	12.57 ± 1.25	13.03 ± 2.11
UKF-NB-3 ^r RITA ^{10μM} I	wt	8.32 ± 1.32	6.64 ± 1.50
UKF-NB-3 ^r RITA ^{10μM} II	wt	5.99 ± 1.80	5.16 ± 1.91
UKF-NB-3 ^r RITA ^{10μM} III	wt	10.79 ± 0.70	0.23 ± 0.04
UKF-NB-3 ^r RITA ^{10μM} IV	A76T ^{2,3}	6.20 ± 2.37	4.89 ± 1.39
UKF-NB-3 ^r RITA ^{10μM} V	wt	9.61 ± 1.96	9.24 ± 1.89
UKF-NB-3 ^r RITA ^{10μM} VI	wt	11.00 ± 2.94	12.33 ± 2.07
UKF-NB-3 ^r RITA ^{10μM} VII	wt	9.05 ± 2.09	0.22 ± 0.06
UKF-NB-3 ^r RITA ^{10μM} VIII	wt	6.18 ± 0.16	5.61 ± 1.01
UKF-NB-3 ^r RITA ^{10μM} IX	wt	13.63 ± 2.54	12.87 ± 2.65
UKF-NB-3 ^r RITA ^{10μM} X	wt	7.93±1.68	9.91 ± 1.04
		nutlin-3 (μM)	nutlin-3 (μM)
UKF-NB-3 ^r Nutlin ^{10μM}	G245C ⁴	36.7 ± 2.9	35.6 ± 4.6
UKF-NB-3 ^r Nutlin ^{10μM} I	wt	34.0 ± 4.8	38.2 ± 3.4
UKF-NB-3 ^r Nutlin ^{10μM} II	wt	40.0 ± 14.0	40.4 ± 3.6
UKF-NB-3 ^r Nutlin ^{10μM} III	wt	35.2 ± 10.1	30.9 ± 3.7
UKF-NB-3 ^r Nutlin ^{10μM} IV	wt	33.6 ± 9.9	34.7 ± 3.9
UKF-NB-3 ^r Nutlin ^{10μM} V	wt	34.3 ± 11.6	29.1 ± 4.1
UKF-NB-3 ^r Nutlin ^{10μM} VI	P278A ³	35.3 ± 14.2	41.2 ± 3.3
UKF-NB-3 ^r Nutlin ^{10μM} VII	D281G ³	40.5 ± 13.9	35.9 ± 6.7
UKF-NB-3 ^r Nutlin ^{10μM} VIII	D281G ³	40.9 ± 4.5	36.2 ± 4.3
UKF-NB-3 ^r Nutlin ^{10μM} IX	D281G ³	47.2 ± 5.1	42.5 ± 6.9

¹ wild-type; ² type of mutation; ³ heterozygote; ⁴ homozygote